Market access update
Market access for regenerative medicines and rare disease therapies
This free collection of case studies offers insights and recommendations for market access for regenerative medicines and rare disease therapies.
Market access strategies for regenerative medicines, and rare and orphan disease treatments are particularly complex. This collection of case studies illustrates some of the challenges and opportunities for manufacturers, including:
- mapping the policy landscape and understand evolving payer requirements for regenerative medicines
- developing value propositions, GVDs, and objections handlers for products indicated for rare diseases
- producing evidence generation plans and prepare HTA submissions using the latest market access technology.
“An overview of early access schemes in key markets was provided in order to highlight opportunities for early access and potential revenue generation.” Client value
“Insights into the opportunities and challenges for orphan drugs in the product pipeline were highlighted.” Client value